A citation-based method for searching scientific literature

Cora N Sternberg, Daniel P Petrylak, Oliver Sartor, J Alfred Witjes, Tomasz Demkow, Jean-Marc Ferrero, Jean-Christophe Eymard, Silvia Falcon, Fabio Calabrò, Nicholas James, Istvan Bodrogi, Peter Harper, Manfred Wirth, William Berry, Michael E Petrone, Thomas J McKearn, Mojtaba Noursalehi, Martine George, Marcel Rozencweig. J Clin Oncol 2009
Times Cited: 253







List of co-cited articles
679 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Ian F Tannock, Ronald de Wit, William R Berry, Jozsef Horti, Anna Pluzanska, Kim N Chi, Stephane Oudard, Christine Théodore, Nicholas D James, Ingela Turesson,[...]. N Engl J Med 2004
40

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Johann Sebastian de Bono, Stephane Oudard, Mustafa Ozguroglu, Steinbjørn Hansen, Jean-Pascal Machiels, Ivo Kocak, Gwenaëlle Gravis, Istvan Bodrogi, Mary J Mackenzie, Liji Shen,[...]. Lancet 2010
40

Abiraterone and increased survival in metastatic prostate cancer.
Johann S de Bono, Christopher J Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N Chi, Robert J Jones, Oscar B Goodman, Fred Saad,[...]. N Engl J Med 2011
38

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu,[...]. N Engl J Med 2015
36

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Daniel P Petrylak, Catherine M Tangen, Maha H A Hussain, Primo N Lara, Jeffrey A Jones, Mary Ellen Taplin, Patrick A Burch, Donna Berry, Carol Moinpour, Manish Kohli,[...]. N Engl J Med 2004
34

Increased survival with enzalutamide in prostate cancer after chemotherapy.
Howard I Scher, Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N Sternberg, Kurt Miller, Ronald de Wit, Peter Mulders, Kim N Chi, Neal D Shore,[...]. N Engl J Med 2012
32

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W Kantoff, Celestia S Higano, Neal D Shore, E Roy Berger, Eric J Small, David F Penson, Charles H Redfern, Anna C Ferrari, Robert Dreicer, Robert B Sims,[...]. N Engl J Med 2010
32

Integrative clinical genomics of advanced prostate cancer.
Dan Robinson, Eliezer M Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J Lonigro, Juan-Miguel Mosquera, Bruce Montgomery, Mary-Ellen Taplin, Colin C Pritchard, Gerhardt Attard,[...]. Cell 2015
28

Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.
Heather H Cheng, Colin C Pritchard, Thomas Boyd, Peter S Nelson, Bruce Montgomery. Eur Urol 2016
172
28

Abiraterone in metastatic prostate cancer without previous chemotherapy.
Charles J Ryan, Matthew R Smith, Johann S de Bono, Arturo Molina, Christopher J Logothetis, Paul de Souza, Karim Fizazi, Paul Mainwaring, Josep M Piulats, Siobhan Ng,[...]. N Engl J Med 2013
25

Alpha emitter radium-223 and survival in metastatic prostate cancer.
C Parker, S Nilsson, D Heinrich, S I Helle, J M O'Sullivan, S D Fosså, A Chodacki, P Wiechno, J Logue, M Seke,[...]. N Engl J Med 2013
25

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
Colin C Pritchard, Joaquin Mateo, Michael F Walsh, Navonil De Sarkar, Wassim Abida, Himisha Beltran, Andrea Garofalo, Roman Gulati, Suzanne Carreira, Rosalind Eeles,[...]. N Engl J Med 2016
699
24

Enzalutamide in metastatic prostate cancer before chemotherapy.
Tomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, Yohann Loriot, Cora N Sternberg, Celestia S Higano, Peter Iversen, Suman Bhattacharya, Joan Carles, Simon Chowdhury,[...]. N Engl J Med 2014
22

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
I F Tannock, D Osoba, M R Stockler, D S Ernst, A J Neville, M J Moore, G R Armitage, J J Wilson, P M Venner, C M Coppin,[...]. J Clin Oncol 1996
21

Platinum-based chemotherapy for variant castrate-resistant prostate cancer.
Ana M Aparicio, Andrea L Harzstark, Paul G Corn, Sijin Wen, John C Araujo, Shi-Ming Tu, Lance C Pagliaro, Jeri Kim, Randall E Millikan, Charles Ryan,[...]. Clin Cancer Res 2013
228
20

The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.
Mark M Pomerantz, Sandor Spisák, Li Jia, Angel M Cronin, Istvan Csabai, Elisa Ledet, A Oliver Sartor, Irene Rainville, Edward P O'Connor, Zachary T Herbert,[...]. Cancer 2017
130
18

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
William Kevin Kelly, Susan Halabi, Michael Carducci, Daniel George, John F Mahoney, Walter M Stadler, Michael Morris, Philip Kantoff, J Paul Monk, Ellen Kaplan,[...]. J Clin Oncol 2012
356
17

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Howard I Scher, Susan Halabi, Ian Tannock, Michael Morris, Cora N Sternberg, Michael A Carducci, Mario A Eisenberger, Celestia Higano, Glenn J Bubley, Robert Dreicer,[...]. J Clin Oncol 2008
17

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
Elena Castro, Chee Goh, David Olmos, Ed Saunders, Daniel Leongamornlert, Malgorzata Tymrakiewicz, Nadiya Mahmud, Tokhir Dadaev, Koveela Govindasami, Michelle Guy,[...]. J Clin Oncol 2013
394
17

Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.
Elena Castro, Chee Goh, Daniel Leongamornlert, Ed Saunders, Malgorzata Tymrakiewicz, Tokhir Dadaev, Koveela Govindasami, Michelle Guy, Steve Ellis, Debra Frost,[...]. Eur Urol 2015
176
15

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
P W Kantoff, S Halabi, M Conaway, J Picus, J Kirshner, V Hars, D Trump, E P Winer, N J Vogelzang. J Clin Oncol 1999
704
14


Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
Karim Fizazi, Howard I Scher, Arturo Molina, Christopher J Logothetis, Kim N Chi, Robert J Jones, John N Staffurth, Scott North, Nicholas J Vogelzang, Fred Saad,[...]. Lancet Oncol 2012
867
12

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
Eugene D Kwon, Charles G Drake, Howard I Scher, Karim Fizazi, Alberto Bossi, Alfons J M van den Eertwegh, Michael Krainer, Nadine Houede, Ricardo Santos, Hakim Mahammedi,[...]. Lancet Oncol 2014
862
12

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert,[...]. J Clin Oncol 2015
12

Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.
Zafeiris Zafeiriou, Diletta Bianchini, Robert Chandler, Pasquale Rescigno, Wei Yuan, Suzanne Carreira, Maialen Barrero, Antonella Petremolo, Susana Miranda, Ruth Riisnaes,[...]. Eur Urol 2019
44
27

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Robert W Ross, Tomasz M Beer, Susanna Jacobus, Glenn J Bubley, Mary-Ellen Taplin, Christopher W Ryan, Jiaoti Huang, William K Oh. Cancer 2008
84
13

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
David I Quinn, Catherine M Tangen, Maha Hussain, Primo N Lara, Amir Goldkorn, Carol M Moinpour, Mark G Garzotto, Philip C Mack, Michael A Carducci, J Paul Monk,[...]. Lancet Oncol 2013
116
11

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
Ian F Tannock, Karim Fizazi, Sergey Ivanov, Camilla Thellenberg Karlsson, Aude Fléchon, Iwona Skoneczna, Francisco Orlandi, Gwenaelle Gravis, Vsevolod Matveev, Sevil Bavbek,[...]. Lancet Oncol 2013
201
11

The status of platinum anticancer drugs in the clinic and in clinical trials.
Nial J Wheate, Shonagh Walker, Gemma E Craig, Rabbab Oun. Dalton Trans 2010
777
11

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Emmanuel S Antonarakis, Changxue Lu, Hao Wang, Brandon Luber, Mary Nakazawa, Jeffrey C Roeser, Yan Chen, Tabrez A Mohammad, Yidong Chen, Helen L Fedor,[...]. N Engl J Med 2014
11

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
11

BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.
Z Kote-Jarai, D Leongamornlert, E Saunders, M Tymrakiewicz, E Castro, N Mahmud, M Guy, S Edwards, L O'Brien, E Sawyer,[...]. Br J Cancer 2011
229
11

Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review.
S Hager, C J Ackermann, M Joerger, S Gillessen, A Omlin. Ann Oncol 2016
44
25

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
M Dror Michaelson, Stephane Oudard, Yen-Chuan Ou, Lisa Sengeløv, Fred Saad, Nadine Houede, Peter Ostler, Arnulf Stenzl, Gedske Daugaard, Robert Jones,[...]. J Clin Oncol 2014
118
10

Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
Howard I Scher, Xiaoyu Jia, Kim Chi, Ronald de Wit, William R Berry, Peter Albers, Brian Henick, David Waterhouse, Dean J Ruether, Peter J Rosen,[...]. J Clin Oncol 2011
179
10

Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
Karim Fizazi, Celestia S Higano, Joel B Nelson, Martin Gleave, Kurt Miller, Thomas Morris, Faith E Nathan, Stuart McIntosh, Kristine Pemberton, Judd W Moul. J Clin Oncol 2013
138
10

The mutational landscape of lethal castration-resistant prostate cancer.
Catherine S Grasso, Yi-Mi Wu, Dan R Robinson, Xuhong Cao, Saravana M Dhanasekaran, Amjad P Khan, Michael J Quist, Xiaojun Jing, Robert J Lonigro, J Chad Brenner,[...]. Nature 2012
10

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Christopher J Sweeney, Yu-Hui Chen, Michael Carducci, Glenn Liu, David F Jarrard, Mario Eisenberger, Yu-Ning Wong, Noah Hahn, Manish Kohli, Matthew M Cooney,[...]. N Engl J Med 2015
10

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
Himisha Beltran, Davide Prandi, Juan Miguel Mosquera, Matteo Benelli, Loredana Puca, Joanna Cyrta, Clarisse Marotz, Eugenia Giannopoulou, Balabhadrapatruni V S K Chakravarthi, Sooryanarayana Varambally,[...]. Nat Med 2016
708
10

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Nicholas D James, Matthew R Sydes, Noel W Clarke, Malcolm D Mason, David P Dearnaley, Melissa R Spears, Alastair W S Ritchie, Christopher C Parker, J Martin Russell, Gerhardt Attard,[...]. Lancet 2016
10

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Howard I Scher, Michael J Morris, Walter M Stadler, Celestia Higano, Ethan Basch, Karim Fizazi, Emmanuel S Antonarakis, Tomasz M Beer, Michael A Carducci, Kim N Chi,[...]. J Clin Oncol 2016
618
10

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
9

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
9

Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.
Ana M Aparicio, Li Shen, Elsa Li Ning Tapia, Jing-Fang Lu, Hsiang-Chun Chen, Jiexin Zhang, Guanglin Wu, Xuemei Wang, Patricia Troncoso, Paul Corn,[...]. Clin Cancer Res 2016
125
9

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.
Johann S de Bono, Howard I Scher, R Bruce Montgomery, Christopher Parker, M Craig Miller, Henk Tissing, Gerald V Doyle, Leon W W M Terstappen, Kenneth J Pienta, Derek Raghavan. Clin Cancer Res 2008
8

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
Dominik R Berthold, Gregory R Pond, Freidele Soban, Ronald de Wit, Mario Eisenberger, Ian F Tannock. J Clin Oncol 2008
760
8

What do we know about the reduction of Pt(IV) pro-drugs?
Ezequiel Wexselblatt, Dan Gibson. J Inorg Biochem 2012
171
8

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.
J Chad Brenner, Bushra Ateeq, Yong Li, Anastasia K Yocum, Qi Cao, Irfan A Asangani, Sonam Patel, Xiaoju Wang, Hallie Liang, Jindan Yu,[...]. Cancer Cell 2011
309
8

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.